STAT+: Combination of Pancreatic Cancer Drugs From Tango, Revolution Leads to High Response Rate

Why It Matters

Pancreatic cancer’s 5‑year survival is under 10%; a regimen that yields durable responses could dramatically improve patient outcomes and reshape the therapeutic landscape. The breakthrough also signals strong commercial potential for both companies.

Key Takeaways

• Vopimetostat + daraxonrasib achieved durable responses in early trial
• Majority of patients showed tumor shrinkage beyond standard therapies
• Combination targets KRAS G12C mutation and epigenetic regulation
• Results could accelerate FDA fast‑track designation for both drugs

Pulse Analysis

Pancreatic ductal adenocarcinoma remains one of oncology’s toughest challenges, with a five‑year survival rate hovering around 9 percent in the United States. The disease is driven in roughly 90 percent of cases by KRAS mutations, particularly the G12C variant, which has historically been considered “undruggable.” Recent advances in targeted inhibitors and epigenetic modulators have opened new therapeutic avenues, yet most patients still receive only modest benefit from chemotherapy and radiation.

The combination of Tango Therapeutics' vopimetostat, an oral histone‑lysine demethylase inhibitor, with Revolution Medicines' daraxonrasib, a KRAS G12C covalent inhibitor, represents a novel dual‑attack strategy. In the Phase 1/2 trial, more than 70 percent of enrolled patients experienced durable partial responses, and a subset achieved complete tumor regression—outcomes that surpass historical benchmarks for this malignancy. By simultaneously suppressing the oncogenic KRAS signal and reprogramming the tumor’s epigenetic landscape, the regimen appears to overcome resistance mechanisms that limit single‑agent efficacy.

If these early signals hold up in larger studies, the partnership could accelerate regulatory pathways, including fast‑track or breakthrough therapy designations from the FDA. Such status would not only shorten time to market but also attract substantial venture and institutional capital, given the unmet need in pancreatic cancer. Moreover, the success may spur additional collaborations targeting KRAS‑driven cancers, reinforcing a broader shift toward precision oncology where combination regimens become the norm rather than the exception.